Cargando…
Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
BACKGROUND: The C-TASK-FORCE phase I/II and Danish randomized phase II trials reported the promising efficacy of trifluridine/tipiracil (TAS102) plus bevacizumab (BEV) in patients with chemorefractory metastatic colorectal cancer (mCRC). However, there had been no direct comparative phase III trial...
Autores principales: | Chida, Keigo, Kotani, Daisuke, Nakamura, Yoshiaki, Kawazoe, Akihito, Kuboki, Yasutoshi, Shitara, Kohei, Kojima, Takashi, Taniguchi, Hiroya, Watanabe, Jun, Endo, Itaru, Yoshino, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064512/ https://www.ncbi.nlm.nih.gov/pubmed/33959196 http://dx.doi.org/10.1177/17588359211009143 |
Ejemplares similares
-
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019) -
Biomarkers of Trifluridine-Tipiracil Efficacy
por: Voutsadakis, Ioannis A.
Publicado: (2021) -
Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis
por: Yoshino, Takayuki, et al.
Publicado: (2023) -
RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer
por: Koumarianou, Anna, et al.
Publicado: (2023) -
Trifluridine/Tipiracil: Old Drug, New Tricks
por: Jeffers, Kate D.
Publicado: (2016)